Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT01751438 Completed - Prostate Cancer Clinical Trials

Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)

Start date: March 18, 2013
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if treatment with standard systemic therapy (androgen deprivation therapy or bilateral orchiectomy) in combination with surgery or radiation therapy is more effective at controlling prostate cancer than standard systemic therapy alone. The safety of this treatment combination will also be studied.

NCT ID: NCT01748500 Completed - Prostate Cancer Clinical Trials

Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer

Start date: January 2013
Phase: Phase 2
Study type: Interventional

The main objectives of this trial are: 1. To assess the activity and safety of pantoprazole and docetaxel (with prednisone) in men with metastatic CRPC who have not received prior chemotherapy. 2. To evaluate archival prostate cancer tissue of men included in the clinical trial for evidence of autophagy using IHC for LC3B, ATG5, p62 as well as ERG. 3. To evaluate pharmacokinetic interactions of pantoprazole with docetaxel.

NCT ID: NCT01744366 Completed - Prostate Cancer Clinical Trials

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

PANDA
Start date: January 2013
Phase: Phase 3
Study type: Interventional

One month degarelix/comparator treatment for prostate cancer in Chinese population

NCT ID: NCT01744262 Completed - Prostate Cancer Clinical Trials

A Comparison of Totally Intravenous and Inhalation Anesthesia for Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy

Start date: May 2011
Phase: N/A
Study type: Interventional

Robot-assisted laparoscopic radical prostatectomy (RALRP) has gained popularity during the past decade and has widely replaced conventional open prostatectomy in many institutions due to reduced blood loss, nerve sparing, less postoperative pain and shorter hospital stay. However, laparoscopic surgery is performed with intraperitoneal carbon dioxide insufflation, which leads to increased intraocular pressure (IOP). In particular, robot-assisted laparoscopic radical prostatectomy (RALRP) usually requires a steep Trendelenburg position and often prolonged insufflation times, which is known to effect the increase in IOP during surgery and may result in ophthalmic complications such as postoperative vision loss (POVL). The majority of patients undergoing RALRP is old aged and often present with comorbidities. Advanced age, underlying diabetes mellitus (DM) or hypertension renders the patient vulnerable to damage due to increased IOP. Moreover, the possibility of the patient having undiagnosed glaucoma is also increased, and therefore methods to prevent such complications are needed. As of now, intravenous hypnotic agents, inhalation anesthetics and opioids have been reported to decrease IOP by relaxing extraocular muscle tone and increasing aqueous humour outflow to some extent. Among these agents, propofol has been reported to be more effective than other inhalational anesthetics in decreasing IOP. The goal of this prospective, randomized controlled trial is to compare the effect of propofol and sevoflurane on IOP in patients undergoing RALRP in the steep Trendelenburg position with carbon dioxide pneumoperitoneum.

NCT ID: NCT01742962 Completed - Prostate Cancer Clinical Trials

Prevalence of Neglected Side Effects to Radical Prostatectomy

Start date: December 2012
Phase: N/A
Study type: Observational

The purpose of this exploratory data collection is to strengthen our knowledge of some of the rarer distresses following surgical removal of the prostate. In general these are: - Side effects related to sexuality, including: - Altered perception of orgasm, - Orgasm associated pain, - Penile shortening and deformity. - Side effects related to urinary incontinence. - Urinary tract infection after operation. - Influence of distress on sexual quality of life. - Influence of distress on the patient´s sex drive. In addition information on a range of demographics and information on the patient´s erectile function will be collected.

NCT ID: NCT01729676 Completed - Prostate Cancer Clinical Trials

Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation

FACT
Start date: May 2013
Phase: N/A
Study type: Observational

French epidemiological data have shown a heterogeneous distribution of the risk of mortality from prostate cancer according to region. The main objective is to describe the distribution of prostate cancer stages when first line hormonal therapy is introduced (overall and by region).

NCT ID: NCT01729442 Completed - Prostate Cancer Clinical Trials

Assessment of HIFU-induced Prostate Necrosis With Shear-wave Ultrasound Elastography

IDITOP-1
Start date: October 2012
Phase: N/A
Study type: Interventional

Transrectal High-intensity Focused Ultrasound (HIFU) is a minimally-invasive therapy for prostate cancer that is currently assessed in two indications: as a first-line treatment (either total or focal) for patients who are not eligible for surgery and as a salvage treatment of local recurrences after radiotherapy. It has recently been shown that Contrast-Enhanced Ultrasound (CEUS) can accurately assess the position and volume of tissue destruction at the end of prostate HIFU ablation. This can provide live feedback regarding the amount of residual non ablated tissue after HIFU treatment, which could allow immediate re-treatment in case of unsatisfactory result. CEUS requires the injection of micro-bubbles of sulphur hexafluoride (Sonovue, Bracco, Milan, Italy) which can, at least in theory, interfere with HIFU treatment. Therefore, it is necessary to wait 20 to 30 minutes before re-treating the patient. Shear-wave ultrasound elastography (SWUE, Supersonic Imagine, Aix-en-Provence, France) can quantify tissue stiffness. Moreover, post-HIFU necrosis is known to be stiffer than undestroyed prostate tissue. Therefore, SWUE could be an alternative to CEUS, and the purpose of this study is to evaluate the accuracy of SWUE in depicting the position and volume of therapeutic necrosis after prostate cancer High-Intensity Focused Ultrasound (HIFU) ablation. The present study is an exploratory, monocentric, prospective, descriptive study. Three groups of 10 patients with prostate cancer will be evaluated: patients referred for first-line prostate HIFU ablation, patients referred for first-line HIFU hemi-ablation (focal treatment) and patients referred for salvage HIFU after radiotherapy. SWUE will be obtained the day before HIFU ablation (D-1), immediately after HIFU ablation (D0) and the following day (D+1). CEUS will be performed immediately after HIFU ablation and D0 SWUE. The primary endpoint is the comparison of the thickness of undestroyed parenchyma measured by SWUE and CEUS. The secondary endpoints are: - The evolution of shear elasticity within the treated area measured by SWUE at D-1, D0 and D+1, - Adverse events related to SWUE. The study will last 40 months.

NCT ID: NCT01717053 Completed - Prostate Cancer Clinical Trials

Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

Start date: January 17, 2014
Phase: Phase 2
Study type: Interventional

The addition of abiraterone acetate to standard treatment of radiotherapy and short-term androgen deprivation will increase the frequency of undetectable PSA.

NCT ID: NCT01715129 Completed - Prostate Cancer Clinical Trials

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

DKP 3M SC
Start date: January 2013
Phase: Phase 3
Study type: Interventional

Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.

NCT ID: NCT01715064 Completed - Prostate Cancer Clinical Trials

Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients

Start date: July 2012
Phase: Phase 2/Phase 3
Study type: Interventional

In Canadian men, prostate cancer (PCa) is the most prevalent form of cancer and the third leading cause of cancer-related death. Unfortunately, PCa survivors are often burdened with feelings of anxiety and depression associated with the disease and associated treatments. Short-term exercise interventions (8-24 weeks) have improved psychosocial well-being in this population, but the impact of single bouts of exercise and related psychological or neurological changes have never been studied. The primary objective of the proposed study is to examine the effect of an acute bout of exercise on neurophysiological and psychological indicators of well-being in a randomized controlled trial (RCT) of 36 men with PCa. Participants will be randomly assigned to the intervention (60 min exercise) or control (60 min of television) and will undergo a brief neurological test (cortical silent period) and psychological questionnaires before and after their group assignment.